| 000 | 01782 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250515182932.0 | ||
| 264 | 0 | _c20100407 | |
| 008 | 201004s 0 0 eng d | ||
| 022 | _a1365-2893 | ||
| 024 | 7 |
_a10.1111/j.1365-2893.2009.01157.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRodriguez-Torres, M | |
| 245 | 0 | 0 |
_aFactors associated with rapid and early virologic response to peginterferon alfa-2a/ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C population. _h[electronic resource] |
| 260 |
_bJournal of viral hepatitis _cFeb 2010 |
||
| 300 |
_a139-47 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAlanine Transaminase _xblood |
| 650 | 0 | 4 |
_aAntiviral Agents _xadministration & dosage |
| 650 | 0 | 4 | _aBody Mass Index |
| 650 | 0 | 4 | _aEthnicity |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHepacivirus _xisolation & purification |
| 650 | 0 | 4 |
_aHepatitis C, Chronic _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInterferon alpha-2 |
| 650 | 0 | 4 |
_aInterferon-alpha _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPolyethylene Glycols _xadministration & dosage |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aRecombinant Proteins |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 |
_aRibavirin _xadministration & dosage |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aViral Load |
| 700 | 1 | _aSulkowski, M S | |
| 700 | 1 | _aChung, R T | |
| 700 | 1 | _aHamzeh, F M | |
| 700 | 1 | _aJensen, D M | |
| 773 | 0 |
_tJournal of viral hepatitis _gvol. 17 _gno. 2 _gp. 139-47 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1365-2893.2009.01157.x _zAvailable from publisher's website |
| 999 |
_c19080160 _d19080160 |
||